Stock Performance and Price Movement
On 28 Nov 2025, Mangalam Drugs and Organics opened at Rs.28.07, representing a gap down of 4.98% from the previous close. The stock traded at this level throughout the day, touching an intraday low of Rs.28.07, which is now its lowest price point in the last 52 weeks. This marks a continuation of a nine-day losing streak, during which the stock has declined by approximately 54.58% in returns.
The stock’s current price is substantially below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent bearish trend. This underperformance is further highlighted by the stock lagging its sector by 5.12% on the day.
Comparison with Market Benchmarks
While Mangalam Drugs and Organics has been on a downward trajectory, the broader market has shown resilience. The Sensex opened flat but gained 0.1% to trade at 85,807.16 points, remaining just 0.29% below its 52-week high of 86,055.86. The index is supported by bullish moving averages, with the 50-day moving average positioned above the 200-day moving average, signalling a positive market environment. Mega-cap stocks have led this upward momentum, contrasting with the performance of Mangalam Drugs and Organics.
Over the past year, Mangalam Drugs and Organics has recorded a total return of -73.79%, a stark contrast to the Sensex’s 8.51% gain over the same period. The stock’s 52-week high was Rs.129.90, underscoring the extent of the decline to the current low.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Financial Health and Profitability Metrics
Mangalam Drugs and Organics has reported negative results for the last three consecutive quarters. The most recent quarterly profit after tax (PAT) stood at a loss of Rs.7.35 crores, reflecting a decline of 201.2% compared to the previous four-quarter average. Net sales for the quarter were recorded at Rs.49.54 crores, the lowest in recent periods, while interest expenses reached Rs.5.03 crores, the highest recorded in the same timeframe.
The company’s long-term financial strength is considered weak, with a high debt-to-EBITDA ratio of 5.66 times, indicating limited capacity to service debt obligations. Return on equity (ROE) averaged 5.83%, signalling modest profitability relative to shareholders’ funds.
Shareholding and Market Risks
A notable factor contributing to the stock’s pressure is the high proportion of pledged promoter shares, which currently stands at 34.58%. This represents an increase of 21.35% over the last quarter. Elevated pledged shareholding can exert additional downward pressure on the stock price, particularly in declining markets.
Over the past year, the stock’s profits have fallen by 306.3%, while its returns have been negative. The stock’s valuation is considered risky relative to its historical averages, and it has consistently underperformed the BSE500 index over the last three annual periods.
Why settle for Mangalam Drugs and Organics ? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Sector Context and Broader Market Environment
Mangalam Drugs and Organics operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance in recent times. While the broader market indices have shown resilience, the company’s stock has diverged significantly from sector trends. The stock’s current valuation and financial metrics reflect ongoing challenges in maintaining profitability and managing debt levels.
The company’s share price decline to Rs.28.07 represents a critical technical level, marking the lowest point in a year and underscoring the extent of the market’s reassessment of its prospects.
Summary of Key Data Points
The following figures encapsulate the recent performance and financial standing of Mangalam Drugs and Organics:
- 52-week low price: Rs.28.07
- 52-week high price: Rs.129.90
- One-year stock return: -73.79%
- Sensex one-year return: 8.51%
- Debt to EBITDA ratio: 5.66 times
- Average Return on Equity: 5.83%
- Latest quarterly PAT: Rs.-7.35 crores
- Latest quarterly net sales: Rs.49.54 crores
- Latest quarterly interest expense: Rs.5.03 crores
- Promoter share pledged: 34.58%
The stock’s recent price action and financial indicators highlight the challenges faced by Mangalam Drugs and Organics in the current market environment.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
